Floatz Rating
C39/100
Confidence
Indicative
Sponsor
Cedars-Sinai Medical Center
Modality
UNKNOWN
Development Phase
Early Phase 1
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
24Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT02653833CT.gov The Study of Skeletal Muscle Blood Flow in Becker Muscular Dystrophy | — | Terminated | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95Indicative
Detailed axis rationale is planned and will be published soon.
Same indication · Muscular Dystrophy
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Beetroot Juice - Active (this asset) | Cedars-Sinai Medical Center | Early P1 | C · 39 |
| gsk2402968 | GlaxoSmithKline | P3 | BB |
| Ataluren | PTC Therapeutics | P3 | B |
| Tadalafil | University of Florida | P2 | B |
| Zeleciment Rostudirsen | Dyne Therapeutics | P3 | B |
| Enalapril | InCor Heart Institute | P3 | B |
| Aoc 1044 | Avidity Biosciences, Inc. | P3 | B |
| Deramiocel | Capricor Inc. | P3 | B |
| Human Allogeneic Cardiosphere-Derived Cells | Capricor Inc. | P2 | CCC |
+2 more in the Muscular Dystrophy cohort
Other indications for Beetroot Juice - Active
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Sickle Cell Disease | — | P2 | CCC · 51 |
| Stroke Disorder | — | P2 | CCC · 48 |
| Ischemic Stroke | — | P2 | CCC · 48 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Beetroot Juice - Active in Muscular Dystrophy. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 14, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/beetroot-juice-active-muscular-dystrophy
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →